Shots:
- The approval is based on the P-III program including 8 studies evaluating Evrenzo in 9600 patients with symptomatic anemia associated with CKD, regardless of dialysis status & prior ESA treatment. Following the EC’s approval, FibroGen to receive $120M milestones along with royalties based upon EU sales
- The results demonstrated that the therapy was effective in maintaining target Hb levels & safety profile is reflective for CKD populations compared to ESAs
- Roxadustat is a HIF-PH inhibitor & is approved in EU member states, including the EEA countries, Japan, China, Chile & South Korea for the same indication in adult patients on DD & NDD
Click here to read full press release/ article | Ref: Astellas | Image: Behance
The post Astellas and FibroGen’s Evrenzo (roxadustat) Receive EC’s Approval for Symptomatic Anemia Associated with Chronic Kidney Disease first appeared on PharmaShots.
